Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.

Background: To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 × 1010 viral particles per 0.5 mL dose), we conducted a single-dose, randomised, double-blind, placebo-controlled, parallel group (3:1 Ad5-nCoV:placebo), phase 3 trial (Prometheus).

Methods: From 11-September-2020 to 05-May-2021, across six sites in the Russian Federation, 496 participants were injected with either placebo or Ad5-nCoV expressing the full-length spike (S) protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

[Assessment of the effectiveness of rehabilitation measures in day hospitals working in the framework of the territorial-team system].

In conditions of a wide use of psychopharmacological drugs the main trend in the activities of a day hospital is prevention of admissions to a mental hospital by elimination of relapses and exacerbations in these patients. Partial hospitalization and consolidation of the results of hospital treatment (stabilization of remissions in the patients, treated in a hospital) must be accomplished with the aid of a complex of psycho-social influences against the background of psychopharmacotherapy. In order to stabilize remissions patients with different types and depths of remissions may be transferred from a mental hospital to a day hospital.